XNYS
CNC
Market cap31bUSD
Oct 08, Last price
64.54USD
1D
-0.69%
1Q
-4.17%
Jan 2017
128.42%
IPO
4,537.59%
Name
Centene Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.
Related entities
Subsidiaries
CIRCLE HEALTH GROUP LIMITED
Key people
Susan Smith
Chief Operating Officer · since 2024
Tanya Mcnally
Chief People Officer · since 2023
Andrew Asher
Chief Financial Officer, Executive Vice President · since 2021
Ken Yamaguchi
Executive Vice President, Chief Medical Officer · since 2015
Rich Fisher
Senior Vice President, Medicare Chief Executive Officer · since 2021
Katie Casso
Senior Vice President - Finance, Chief Accounting Officer, Corporate Controller · since 2024
Suzy DePrizio
Senior Vice President, Chief Marketing Officer · since 2021
Christopher Koster
Executive Vice President, General Counsel, Secretary · since 2021
Kenneth Burdick
Director · since 2022
Sarah London
Chief Executive Officer, Director · since 2022
Jessica Blume
Independent Director · since 2018
Independent Director · since 2022
Independent Director · since 2023
Independent Director · since 2022
Non-Executive Independent Chairman of the Board · since 2023
Independent Director · since 2022
Independent Director · since 2022
Independent Director · since 2025
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
1209 ORANGE ST
WILMINGTON, DE 19801
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||